Stay updated on Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.5.5 is now shown, replacing the previous v3.5.4. This indicates a minor update to the page content or structure without altering the underlying study information.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page now displays a new revision tag 'Revision: v3.5.4', replacing the previous 'Revision: v3.5.3'. This reflects a minor version update to the page rather than any substantive changes to the study details.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page’s displayed revision/version marker was incremented from v3.5.2 to v3.5.3, reflecting a site release/update rather than a change to the study information.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check76 days agoChange DetectedFooter and policy updates were added, including release notes, privacy and accessibility information, and government links.SummaryDifference100%

- Check83 days agoChange DetectedFooter/navigation items and several archived study documents were removed. The essential trial data remains accessible on the page.SummaryDifference22%

Stay in the know with updates to Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and CC-486 in Platinum-resistant Ovarian Cancer Clinical Trial page.